Private EquityRIA · CRD 288712SEC-Registered

Updated:

F-Prime Capital

F-Prime Capital is a $5.3B global venture firm born from Fidelity Investments, investing across healthcare, enterprise, fintech, and crypto.

F-Prime Capital logo

F-Prime Capital

F-Prime Capital is an SEC-registered investment adviser in Overland Park, Kansas, registered since 2017. The firm manages $39.1 billion in assets, with $19.6 billion on a discretionary basis. It has 446 employees and 266 investment advisers.

General information

Firm type

Private Equity

Year founded

AUM

$5.3B (per the firm, 2026)

Location

Region

North America

Country

United States

City

Cambridge

Corporate office

Cambridge, United States

Additional offices

Chicago, IL · Abu Dhabi, UAE

Sector focus

Life SciencesEnterprise SoftwareFinTechCrypto / BlockchainFrontier TechHealthTechMedTech

Frequently asked questions

What is the relationship between F-Prime Capital and Fidelity Investments?

F-Prime Capital is an independent venture capital firm that traces its roots to the venture arm of Fidelity Investments. Fidelity, founded by Edward C. Johnson II, remains the anchor limited partner, but F-Prime operates autonomously with its own investment committee, offices, and brand. This structure gives F-Prime access to patient, permanent capital without functioning as a captive corporate VC.

How does F-Prime split its investments between healthcare and technology?

F-Prime runs two dedicated practices: one for healthcare and one for technology. The healthcare team invests across therapeutics, medtech, and healthtech services. The technology team covers enterprise software, fintech, frontier tech, and crypto. Both teams operate with a stage-agnostic mandate, investing from seed through late-stage venture.

Does F-Prime Capital only invest in U.S. companies?

No. F-Prime's portfolio spans North America, Europe, Asia, and South America. The firm maintains offices in Cambridge, Chicago, and Abu Dhabi, which supports the international scope of its investment activity.

What stages does F-Prime Capital target?

F-Prime is early-stage focused by choice but stage-agnostic in practice. The firm can and does invest from seed rounds through to late-stage venture financings. This flexibility applies across both its healthcare and technology practices.

Who makes investment decisions at F-Prime?

F-Prime operates its own investment committee independent of Fidelity Investments. The partnership includes scientists, engineers, physicians, and operators. The firm has not publicly disclosed a centralized list of current managing partners or the full composition of its investment committee.

Does F-Prime have a philanthropic arm or affiliated ecosystem programs?

F-Prime runs a fellows program that has supported dozens of healthtech and biotech startups, particularly through its Boston ecosystem. The firm's website also aggregates a job board for roles at its portfolio companies, suggesting a deliberate effort to operate as a talent platform in addition to a venture investor.

What is F-Prime Capital's exposure to crypto and frontier tech?

Crypto and frontier tech are two disclosed technology sub-sectors where F-Prime actively invests. The firm's portfolio includes Coinbase Global, a major crypto exchange platform. Frontier tech investments extend across robotics, space, and emerging compute paradigms, though specific current holdings beyond Coinbase are not individually detailed on the firm's public portfolio page.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on private equity firms?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Cambridge Private Equity profiles